Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06616038
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-18
Brief Title:
Heart Failure Biomarkers
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Biomarker Assessment in Heart Failure with Reduced Systolic Function HFrEF and Preserved Systolic Function HFpEF
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BIOHF
Brief Summary:
Systemic inflammation is closely associated with the development and progression of heart failure HF The study assessed the fibrinalbumin FAR ratio a very important biomarker as a prognostic indicator of HE Study population is composed by patients who were addicted with heart failure diagnosed for the first time or already under treatment NYHA class II-IV and reduced ejection fraction HFrEF or preserved ejection fraction HFpEF
Detailed Description:
Prospective observational single-center study which involves the enrollment of patients affected by heart failure of first diagnosis or already in therapy who will be subjected to an analysis of the Albuminfibrinogen ratio Subjects will not be subjected to specific visits or services for the study clinical and anamnestic data will be collected during routine visits
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None